Özgür CAN, Savas Volkan KISIOĞLU, Sakin TEKİN, Mehmet SARGIN

Tip 2 Diyabet Hastalarının Tedavilerine Sitagliptin Eklenmesinin Glisemik Kontrol Üzerine Etkisi

Amaç: Bir dipeptidil peptidaz-4 (DPP-4) inhibitörü olan sitagliptin, metformin tedavisine ek olarakkullanıldığında etkili ve iyi tolere edilen inkretin temelli bir tedavidir. Sitagliptinin metforminmonoterapisine eklenmesinin HbA1c, açlık kan şekeri (AKŞ) ve vücut ağırlığı (VA) üzerine 52 haftalıksonuçlarını değerlendirmeyi amaçladık.Materyal ve Metot: Çalışmaya metformin monoterapisi alırken tedavisine sitagliptin eklenen ve 12 ayboyunca sitagliptin tedavisine devam eden 44 hasta dahil edildi. Olgularda yaş, cinsiyet, kilo, vücut kitleindeksi (VKİ), AKŞ, HbA1c, üre, kreatinin, total kolesterol, trigliserit, LDL, HDL, alanin aminotransferazve aspartat aminotrensferaz parametreleri değerlendirmeye alındı.Bulgular: Çalışmaya alınan 44 hastanın ortalama yaşı 58,5±8,9 yıl idi. Başlangıçta, VA: 80,36±11,72 kg veVKİ: 31,14±5,16 kg/m2 idi. Başlangıçtaki HbA1c düzeyi: %7,5±0,64 olarak saptandı. HbA1c seviyesininbaşlangıç değerlere göre düşüş oranının sırasıyla 3. ayda %0,82; 6. ayda %0,86 ve 12. ayda % 0, 9 olduğugörüldü. HbA1c düşüşü başlangıca göre tüm aylarda istatistiksel olarak anlamlı bulundu. AKŞseviyesinde başlangıç değerlerine göre sırasıyla 3. ayda 23,65 mg/dl, 6. ayda 26,07 mg/dl ve 12. ayda 23,55mg/dl düşme olduğu görüldü. AKŞ’de düşüş, başlangıç değerleri ile karşılaştırıldığında tüm aylardaistatistiksel olarak anlamlıydı. AKŞ düşüşün 12 ay boyunca istikrarlı bir şekilde devam ettiği görüldü.Sonuç: Metformin monoterapisi kullanımına rağmen yeterli glisemik kontrol sağlanamayan (özellikleHbA1c düzeyi %7-8) tip 2 diyabetli hastalarda tedaviye sitagliptin eklenmesi etkin ve iyi tolere edilen birseçenektir.

Sitagliptin Add-on to Metformin Therapy: The Efficacy of Dual Therapy on Glycemic Control in Type 2 Diabetes

Objectives: Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is an effective and well tolerated incretin-based therapy when used in addition to metformin therapy. We aimed to evaluate the 52-week results of adding sitagliptin to metformin monotherapy on HbA1c, fasting blood glucose (FBG) and body weight (BW). Materials and Methods: The study included 44 patients who were treated with sitagliptin and continued to sitagliptin for 12 months while receiving metformin monotherapy. Age, sex, weight, body mass index,FBG, HbA1c, urea, creatinine, total cholesterol, triglyceride, LDL, HDL, alanine aminotransferase and aspartate aminotrensferase parameters were evaluated. Results: The mean age of the 44 patients included in the study was 58.5 ± 8.9 years. Initially, BWand BMI were80.36 ± 11.72 kg and 31.14 ± 5.16 kg / m2 ; respectively. The initial HbA1c level was 7.5 ± 0.64%. The rates of HbA1cdecline according to the initial level were 0.82%, 0.86% and 0.9% at 3th, 6th and 12th months; respectively. There were statistically significant results when the baseline HbA1c level was compared to 3th, 6th and 12th months’ HbA1c levels. FBG level decreased 23.65 mg /dl, 26.07 mg / dl and 23.55 mg / dl at 3th, 6th and 12th months; respectively. There were also statistically significant results when the baseline FBG level was compared to 3th, 6th and 12th months’ FBG levels. It was observed that the decline in the FBG continued steadily for 12 months. Conclusion: Addition of sitagliptin to treatment is an effective and well tolerated option in patients with type 2 diabetes who are not able to achieve adequate glycemic control despite metformin monotherapy (especially HbA1c level 7-8%).

PDF

___

1. Diabetes Care 2018;41(Suppl. 1):S1–S2 | https://doi.org/10.2337/dc18-SINT01.
2. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus—progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005–2012.
3. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes scientific review. JAMA 2002;287:360–72.
4. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638–43.
5. Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes, Obesity and Metabolism2011;13:160-8.
6. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9(2):194-205.
7. Seck T, Nauck M, Sheng D, et al. Sitagliptin Study 024 Group. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010;64:562-76.
8. Varım C, Uyanık MŞ, Akçay EÜ ve ark. Effects of DPP-4 inhibitors on HbA1c, haematological parameters , parameters of inflammation in the patients with newly diagnosed Type 2 DM. Ortadogu Medical Journal 2015;7(4):172-7.
9. Scott R, Loeys T, Davies MJ, Engel SS. Sitagliptin Study 801 Group.Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.Diabetes Obes Metab 2008;10:959-69.